VYJUVEK (beremagene geperpavec-svdt)
DERMATOLOGICAL - GENE THERAPY AGENTS · DYSTROPHIC EPIDERMOLYSIS BULLOSA
KRYSTAL BIOTECH
Drug class
Dermatological - Gene Therapy Agents
“Dermatological - Gene Therapy Agents” is a formulary and compendial drug classification rather than a standardized physiological class, primarily established to categorize topical gene-based biologics. Read more about Dermatological - Gene Therapy Agents
2 drugs in this class 2 manufacturers
Drugs in Dermatological - Gene Therapy Agents
ZEVASKYN (prademagene zamikeracel)
DERMATOLOGICAL - GENE THERAPY AGENTS · DYSTROPHIC EPIDERMOLYSIS BULLOSA
ABEONA THERAPEU
Filter & compare in the drug finder →
Opens the drug finder with Dermatological - Gene Therapy Agents preselected. Add indication or manufacturer filters there.
“Dermatological - Gene Therapy Agents” is a formulary and compendial drug classification rather than a standardized physiological class, primarily established to categorize topical gene-based biologics.
Agents in this class, such as beremagene geperpavec, utilize replication-incompetent viral vectors (typically herpes simplex virus type 1) to deliver functional wild-type therapeutic genes directly to cutaneous cells and extracellular matrix environments.
This mechanism enables local synthesis and assembly of deficient structural proteins, restoring tissue integrity without integrating foreign genetic material into the host genome.
Therapeutically, these agents are indicated for the management of severe genetic blistering conditions, specifically dystrophic epidermolysis bullosa caused by mutations in the collagen type VII gene.
-
la.gov
“Dermatological - Gene Therapy Agents” is a formulary and compendial drug classification rather than a standardized physiological class, primarily established to categorize topical gene-based biologics
-
kaiserpermanente.org
“Dermatological - Gene Therapy Agents” is a formulary and compendial drug classification rather than a standardized physiological class, primarily established to categorize topical gene-based biologics
-
nih.gov
Agents in this class, such as beremagene geperpavec, utilize replication-incompetent viral vectors (typically herpes simplex virus type 1) to deliver functional wild-type therapeutic genes directly to cutaneous cells and extracellular matrix environments
-
researchgate.net
Agents in this class, such as beremagene geperpavec, utilize replication-incompetent viral vectors (typically herpes simplex virus type 1) to deliver functional wild-type therapeutic genes directly to cutaneous cells and extracellular matrix environments
-
wa.gov
Therapeutically, these agents are indicated for the management of severe genetic blistering conditions, specifically dystrophic epidermolysis bullosa caused by mutations in the collagen type VII gene
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.